جست‌وجوی استاد و پژوهشگر

• Biomaterials
• Tissue Engineering
• Regenerative Medicine
• +۱۲ مورد دیگر

Professor Hala Zreiqat AM is a leading biomedical engineer at The University of Sydney , serving as the Director of the ARC Training Centre for Innovative BioEngineering . A Fellow of all major Australian academies (AAS, ATSE, FAHMS, FRSN), she develops 3D printed bioceramics for bone regeneration while championing diversity through initiatives like the IDEAL Society and BIOTech Futures mentorship program. Her work bridges academia, clinical practice, and industry in musculoskeletal research . Research Focus: Her lab creates synthetic bone scaffolds that mimic natural bone architecture, strength, and porosity, enabling non-rejected bone regeneration via patient-matched implants. Key applications include orthopaedic, dental, and maxillofacial repair , with over $18M in competitive funding and multiple patents. Current projects explore AI-driven scaffold performance prediction and anti-senescence strategies for aging-related bone loss. Scientific Trends: Recent publications highlight 3D printed nanovoxelated ceramics , antisenescence biomaterials , and multifunctional theranostic platforms . Her team integrates machine learning for scaffold design, atom probe tomography for interface analysis, and two-photon imaging for cellular monitoring in 3D environments. 2021-2022 Fulbright Senior Scholar 2018 NSW Premier's Woman of the Year 2019 Eureka Prize for Innovative Use of Technology Fellow of Australian Academy of Science (2021) Over $18M in research funding Teaching & Leadership: She designed core courses like Tissue Engineering and Nanomaterials in Medicine , mentoring 158 students in 2020 alone. As Chair of CAAR (2020-2023), she strengthens Australia-Arab collaborations. Her lab trains early-career researchers , with alumni now in academia and industry.

Laura Soltمشاهده پروفایل

دانشیار

• Autoimmune Disease
• Cancer Immunotherapy
• Immunometabolism
• +۵ مورد دیگر

Laura Solt, Ph.D. is an Associate Professor in the Department of Immunology and Microbiology at the Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology in Jupiter, Florida. She also serves as Associate Dean of the Skaggs Graduate School of Chemical and Biological Sciences. Dr. Solt began her independent research career at Scripps Florida in 2013 and has established herself as a leading researcher in nuclear receptor biology within the immune system. Her research focuses on understanding the biologically relevant roles of nuclear receptors, particularly RORα and REV-ERBs, in the immune system with emphasis on TH17 cell development and autoimmune disease. Her lab employs a multidisciplinary approach combining molecular biology, genetic techniques, and chemical biology coupled with mouse models of autoimmunity and chronic inflammation. Dr. Solt's laboratory has made significant contributions to understanding how nuclear receptors regulate immune cell function, particularly in TH17-mediated inflammation. Her work has demonstrated roles for RORα and REV-ERBs in TH17 cell development and has developed synthetic ligands to these receptors for potential therapeutic applications in autoimmune diseases. Her extensive publication record shows a clear trajectory of research focused on nuclear receptor signaling in immunity, with recent work expanding into applications for cancer immunotherapy, neuroimmunology, and metabolic aspects of immune cell function. Her articles demonstrate expertise in both basic nuclear receptor mechanisms and translational applications. Ruth L. Kirschstein National Research Service Awards (2010-2013) Dr. Solt actively mentors graduate students including Adrianna Wilson (recipient of NIDDK F31 and Scheller Graduate Student Fellowship) and Sarah Mosure (recipient of NIH NRSA F31 award and Wendy Havran award). Her laboratory receives substantial funding from multiple NIH institutes (NIDDK, NCI, NIAID, NIGMS) as well as the Crohn's & Colitis Foundation. Current research directions include investigating the roles of NR2F6 in TH17 cells, exploring RORα function in CD8 T cells, and developing novel nuclear receptor modulators for therapeutic applications.

Torben Baringtonمشاهده پروفایل

استاد بالینی

• Clinical Immunology
• Cellular Immunotherapy
• CAR T-cell Technology
• +۶ مورد دیگر

Torben Barington is a Clinical Professor at the Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, and a Consultant at the Department of Clinical Immunology, Odense University Hospital. He has held this position since August 2001 and continues to be actively involved in research, teaching, and clinical leadership. MD, University of Copenhagen, 1987 Doctoral Thesis (dr.med.), University of Copenhagen, 1996 Specialist in Clinical Immunology, 1998 His research focuses on cellular immunotherapy of cancer , particularly using CAR T-cell and CAR NK-cell technologies, primary immunodeficiencies , and the B-lymphocyte repertoire and immunoglobulin genes . His work bridges fundamental immunology with clinical applications in oncology and immunodeficiency disorders. His recent publications (2024–2025) highlight advancements in CAR T/NK-cell characterization, cytotoxicity assays, clinical translation, and tumor microenvironment interactions. These works reflect a strong trend toward translational immunology , with emphasis on personalized cancer therapy , single-cell technologies , and clinical trial development . Scientific Awards: Aage og Edith Dyssegaards Fonds æreslegat (1993) Silver Medal, University of Copenhagen (1981) He has supervised over 30 thesis students and currently mentors several graduate students in CAR-based cancer immunotherapies. He serves as an examiner for PhD defenses at both the University of Southern Denmark and the University of Copenhagen. He is also actively involved in national scientific leadership, including as Chairman of the Scientific Committee of the Danish Blood Donor Organization since 2011 and as a member of the Advisory Board for Clinical Immunology in the Region of Southern Denmark since 2007. His research is conducted in collaboration with multidisciplinary teams focusing on cellular immunotherapy , clinical immunology , and translational hematology , often in partnership with Odense University Hospital and national blood and immunology networks.

• Immunology
• Virology
• Inflammation
• +۵ مورد دیگر

Santiago F. González is a Group Leader at the Institute for Research in Biomedicine (IRB) in Bellinzona, Switzerland, and an extraordinary professor at the University of Italian Switzerland (USI). He earned dual PhDs in microbiology (University of Santiago de Compostela, Spain) and immunology (University of Copenhagen, Denmark), followed by postdoctoral work (2007–2011) at Harvard Medical School's Immune Disease Institute under Michael Carroll. PhD in Microbiology, University of Santiago de Compostela PhD in Immunology, University of Copenhagen His research focuses on immune system dynamics during respiratory viral infections, vaccination, and cancer metastasis. Key areas include influenza recognition , lymph node inflammation , and immune cell behavior in vivo. He pioneered studies on C-type lectin receptors (e.g., SIGN-R1) in viral immunity and epigenetic modulators for inflammation. Recent publications highlight his work in epigenetic drug development , nanovaccines , and computational tools for immune cell tracking. His group uses two-photon intravital microscopy and spatial-temporal modeling to dissect immune responses. Scientific awards include three EU Marie Curie Fellowships (2004–2013), enabling his transition to independent research. His collaborations span Harvard, USI, and European institutions, with grants from the EU and Swiss research bodies. His lab at IRB, established via the 2013 Marie Curie Career Integration Grant , develops novel imaging approaches and therapeutic strategies for infectious and immune-mediated diseases.

Joseph P. Bresslerمشاهده پروفایل

دانشیار

• Neurotoxicology
• Environmental Health Sciences
• Metal Transporters
• +۱۲ مورد دیگر

Joseph P. Bressler is an Associate Professor at Johns Hopkins University, jointly affiliated with the Bloomberg School of Public Health and the Krieger School of Arts and Sciences. He is a member of the Department of Environmental Health and Engineering and conducts research at the Kennedy Krieger Institute in Baltimore, Maryland. His work bridges public health, neuroscience, and molecular toxicology, focusing on environmental impacts on brain development. Education: PhD, Rutgers University, 1978 Dr. Bressler’s research centers on neurotoxicology, particularly how environmental pollutants such as lead, cadmium, and aluminum disrupt metal transport systems and affect neurodevelopment. His laboratory investigates the role of iron and other metal transporters at the blood-brain barrier and in glial cells, revealing mechanisms of metal uptake and toxicity. His work has implications for understanding autism, fetal alcohol syndrome, and other neurodevelopmental disorders. His recent publications highlight ongoing research into metal homeostasis, cytotoxicity in cancer and neuronal cell lines, e-cigarette aerosol variability, and epigenetic changes in sex chromosome aneuploidies. The research spans molecular mechanisms, in vitro models, and human health outcomes, demonstrating a multidisciplinary approach to environmental health. Scientific Contributions: Elucidated how lead and cadmium hijack iron transporters to enter the brain Demonstrated aluminum activation of iron uptake pathways in glial cells Investigated flavoring agents like ethyl maltol in enhancing metal toxicity Explored epigenetic and behavioral impacts in rare genetic conditions Dr. Bressler has advised numerous researchers and collaborators across disciplines. His work has been supported by federal and institutional grants, though specific funding details are not provided in the source text. He actively publishes in high-impact toxicology and environmental health journals, with research cited in policy and public health discussions. He leads a research laboratory focused on cellular and molecular mechanisms of neurotoxicity, utilizing in vitro models of the blood-brain barrier, astrocytes, and neuronal cell lines. His team collaborates widely across neuroscience, public health, and environmental engineering domains.

Maria J. Redondoمشاهده پروفایل

استاد

• Type 1 Diabetes
• Genetics of Autoimmune Diseases
• Diabetes Heterogeneity
• +۳ مورد دیگر

Maria J. Redondo is a Professor at Baylor College of Medicine and leads the Maria J. Redondo Lab at Texas Children’s Hospital, focusing on Type 1 Diabetes across four core areas: Genetics for prediction models and trial candidate selection Heterogeneity in diabetes pathogenesis Prevention through clinical trials Atypical Diabetes and Racial/Ethnic Influences Research Trends: Her recent articles emphasize genetic risk modeling, BMI correlations in pediatric diabetes, and HLA studies. The work integrates autoimmunity , metabolic research , and epidemiological analysis . Scientific Awards: Elected to the Society for Pediatric Research (2014) JDRF Early Career Development Award (2002) JDRF Postdoctoral Fellowship (2000) Immunology of Diabetes Society Junior Investigator Award (1998) Mentoring: Dr. Redondo mentors fellows and students in projects like COVID-19 and Diabetes and Racial Differences in Insulin Pump Uptake , with grants from NIH , Medtronic , and Hemsley Charitable Trust .

Raphael Franziniمشاهده پروفایل

دانشیار

• Drug Discovery
• Medicinal Chemistry
• Bioorthogonal Chemistry
• +۳ مورد دیگر

Raphael Franzini serves as Associate Professor of Medicinal Chemistry at the University of Utah, actively contributing to the Biological Chemistry PhD Program. His research pioneers innovative chemical approaches for therapeutic development, with dual focus on DNA-encoded library technologies and bioorthogonal drug delivery systems. His educational foundation includes an M.S. from the Swiss Federal Institute of Technology (Lausanne) and a Ph.D. from Stanford University. This training underpins his group's multidisciplinary methodology combining organic synthesis, bioconjugation, computational modeling, and advanced imaging techniques. Dr. Franzini's research program centers on two transformative areas: First, advancing DNA-encoded library screening through computational integration to identify leads for challenging targets like Tankyrase and Sirtuin 6, with recent work addressing false negatives in machine learning prediction. Second, developing novel bioorthogonal release chemistry using isonitrile-tetrazine reactions for spatiotemporally controlled drug activation, validated in zebrafish models. His group emphasizes both technological innovation and therapeutic translation, with chemistry designed to minimize off-target effects in solid tumors. Analysis of his 15 most recent publications reveals escalating integration of computational methods with experimental library screening, alongside refinement of bioorthogonal release kinetics. The work spans chemical biology, medicinal chemistry, and pharmaceutical sciences, with growing emphasis on machine learning for library data interpretation and in vivo validation of drug-release systems. Dr. Franzini maintains an active research laboratory that provides comprehensive training in cutting-edge drug discovery methodologies. His group culture prioritizes both scientific innovation and researcher development, with projects spanning from fundamental reaction kinetics to therapeutic applications. The lab's infrastructure supports organic synthesis, molecular imaging, and computational analysis for advancing precision therapeutics.

Brent Pageمشاهده پروفایل

دانشیار

• Medicinal Chemistry
• Chemical Biology
• Drug Discovery and Development
• +۱۳ مورد دیگر

Brent Page is an Associate Professor (tenured) in the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC) and maintains a research group at the Karolinska Institute , Department of Oncology and Pathology. His dual affiliation underpins a trans-Atlantic program that integrates cutting-edge chemical biology with medicinal chemistry for anti-cancer drug discovery. Education & Training PhD in Chemistry – University of Toronto (2013) HBSc in Chemistry (Honours) – University of British Columbia (2008) CIHR Postdoctoral Fellow – Karolinska Institute, Sweden (2008–2016) Assistant Professor (non-independent) – Karolinska Institute, Department of Oncology-Pathology (2017–2021) Research Focus Dr. Page’s laboratory operates at the interface of medicinal chemistry and chemical biology , aiming to identify and optimize small-molecule inhibitors for proteins previously considered “undruggable.” Core targets include STAT3, CLIC3, NUDT5/15 and SRPK3 . The group employs cellular thermal shift assays , isothermal ligand-induced resolubilization (ILIRA) , and CeTEAM technologies to quantify target engagement and refine structure–activity relationships in physiologically relevant models of breast cancer, triple-negative breast cancer, leukemia and atopic diseases . Funding & Collaborations His program is supported by Canadian Institutes of Health Research (CIHR) and other national and international agencies. Dr. Page actively participates in UBC’s Accelerated Translational Opioid Research Cluster and welcomes interdisciplinary collaborations and undergraduate research involvement. Equity, Diversity & Inclusion Committed to fostering an inclusive environment, Dr. Page mandates EDI training for all lab members and actively encourages participation from equity-deserving groups.

• Cell Biology
• Biophysics
• Mechanobiology
• +۳ مورد دیگر

Pere Roca-Cusachs Soulere is a Full Professor at the University of Barcelona and Group Leader at the Institute for Bioengineering of Catalonia (IBEC). His research focuses on understanding how cells detect and respond to mechanical signals through physical and molecular mechanisms. He holds significant roles in both academic and research institutions, including leadership in IBEC's Cellular and Molecular Mechanobiology group. Education: PhD in cellular biophysics (2007) from the University of Barcelona Medical School; postdoctoral research at Columbia University (2007–2011). Established his group at IBEC in 2012. Awards include the EMBO Young Investigator Award, City of Barcelona Award, and EBSA Young Investigator Award. Research Interests: Mechanobiology, cellular mechanotransduction, force transmission, nuclear mechanics, and integrin-mediated adhesion. His work bridges biophysics, cell biology, and engineering to study how mechanical forces influence cellular behavior and disease processes. Awards: Recognized for contributions to mechanobiology, including EMBO membership and multiple prestigious awards. His lab develops innovative tools like the MIRO chip to model tumor-immune interactions. Advising & Grants: Leads a multidisciplinary team, collaborating on projects funded by grants focusing on cell mechanics, cancer biology, and tissue engineering. His work integrates experimental and computational approaches to advance understanding of cellular force dynamics. Labs/Teams: Directs the Cellular and Molecular Mechanobiology group at IBEC, a hub for cutting-edge research on mechanosensing and mechanotransduction.

Jacques Archambaultمشاهده پروفایل

استاد

• Human Papillomavirus (HPV)
• Polyomavirus
• Viral DNA Replication
• +۴ مورد دیگر

Dr. Jacques Archambault is a Professor in the Department of Microbiology and Immunology at McGill University , and an associate member of the Division of Experimental Medicine since 2016. His research focuses on the molecular biology and pathogenesis of human papillomaviruses (HPVs) and polyomaviruses (HPyVs), with an emphasis on their replication mechanisms as episomes in host cells. The Archambault laboratory employs functional genomics, proteomics, and chemical biology approaches to identify cellular pathways exploited by these viruses and develop high-throughput assays for screening small molecule inhibitors of viral replication. Analysis of his recent publications reveals a strong focus on HPV and HPyV replication machinery, including studies on the E1 helicase, UAF1-USP1 interactions, and structural characterization of viral proteins involved in DNA replication. His work bridges virology, oncology, and drug discovery, particularly targeting oncogenic HPV types implicated in anogenital and oropharyngeal cancers, as well as HPyVs like BKPyV and JCPyV that cause pathologies in immunosuppressed patients. Current efforts in the lab aim to elucidate the molecular mechanisms by which HPVs and HPyVs replicate their genomes and to develop antiviral therapies targeting these processes. Techniques such as fluorescence anisotropy, NMR spectroscopy, and crystallography are frequently employed to study protein-DNA and protein-protein interactions critical to viral replication.

• Mechanobiology
• Biomechanics
• Organ-on-chip
• +۵ مورد دیگر

Associate Professor Arnold Lining Ju is a biomedical engineer at the University of Sydney's School of Biomedical Engineering, affiliated with multiple institutes including the Heart Research Institute and Sydney Nano Institute. He holds academic positions in both the Faculty of Engineering and Faculty of Medicine & Health. Education: BSc from Peking University, PhD from Georgia Tech and Emory University (USA). Honors include Snow Fellowship, Heart Foundation Future Leader Fellowship, and multiple awards for cardiovascular research innovation. Research focuses on mechanobiology and biomechanics of thrombosis, developing microfluidic devices and organ-on-chip systems. Key projects include AI-driven single-cell nanotools, 3D biofabrication, and anti-thrombotic peptide design. Leads interdisciplinary teams and collaborates internationally with institutions like Harvard and University of Texas. Teaching roles include coordinating advanced cellular biomechanics courses and supervising PhD/Masters students in biomedical engineering and physiology. Over 50 peer-reviewed publications, with contributions to Nature Materials, Nature Communications, and other top journals.

Hang Luمشاهده پروفایل

دانشیار

• Science Communication
• Health Communication
• Environmental Communication
• +۴ مورد دیگر

Hang Lu is an Associate Professor in the Department of Communication and Media at the University of Michigan's College of Literature, Science, and the Arts. He specializes in science, health, environmental, and risk communication (ComSHER), with a focus on media psychology. His research explores audience responses to media messages about sensitive topics and strategies to enhance message effectiveness. Lu holds a Ph.D. in Communication from Cornell University (2018), along with advanced degrees from Cornell, Marquette University, and Central South University in China. He directs the Media and Risk (MaR) Lab and previously served as a postdoctoral fellow at the Annenberg Public Policy Center. His research spans four main areas: 1) emotion dynamics in media responses, 2) predictors of information behaviors, 3) media effects on stigmatization, and 4) AI applications in sensitive domains. He has published in journals like Journal of Communication , Risk Analysis , and Public Understanding of Science , earning multiple top paper awards. As Vice Chair of the Environmental Communication Division at the International Communication Association, Lu contributes to interdisciplinary dialogue. His work addresses critical societal issues such as climate change communication, vaccination hesitancy, and emerging technology ethics.

Hong Hanمشاهده پروفایل

استادیار

• Cancer Biology
• Gene Regulation
• RNA Splicing
• +۵ مورد دیگر

Hong Han is an Assistant Professor in the Department of Biochemistry & Biomedical Sciences within McMaster University's Faculty of Health Sciences and a member of the Centre for Discovery in Cancer Research (CDCR). She holds a Canada Research Chair and leads the Han Lab, which focuses on cancer biology, RNA regulation, and innovative high-throughput technologies for therapeutic discovery. Dr. Han earned her Ph.D. from the University of Toronto (2010-2016) and has established herself as a leading researcher in glioblastoma and alternative splicing regulation. Her interdisciplinary research integrates cancer biology, RNA science, and multilayer gene regulation to uncover mechanisms underlying cancer progression and treatment resistance. Her laboratory pioneers integrated technological platforms for large-scale genetic/drug screening and ultra-high-throughput single-cell profiling. The research focuses on three main areas: alternative splicing regulation in cancer (particularly glioblastoma and prostate cancer), multilayer mechanisms of glioblastoma heterogeneity and microenvironment evolution, and multiplexed screening approaches for therapeutic discovery in treatment-resistant cancers. Analysis of Dr. Han's recent publications reveals a strong emphasis on single-cell technologies to characterize glioblastoma heterogeneity, minimal residual disease states, and tumor-immune interactions. Her work increasingly bridges basic RNA biology with translational applications, particularly in developing novel therapeutic strategies targeting splicing networks and immune evasion mechanisms. Canada Research Chair Dr. Han teaches Advanced Techniques in the Biomedical Sciences (BIOCHEM 734). Her research program is supported by multiple funding sources, as evidenced by her extensive publication record in high-impact journals including Nature, Cell, Molecular Cell, and Nature Communications. She employs a comprehensive approach combining in vitro, in vivo, and patient cohort studies with cutting-edge genomic technologies. The Han Lab has developed innovative multiplexed screening platforms that enable simultaneous interrogation of thousands of conditions, ranging from CAR-T cells to small molecule therapeutics. This approach accelerates the discovery of novel cancer targets and therapeutic strategies for treatment-resistant cancers.

Andreas Bauschمشاهده پروفایل

استاد

• Cellular Biophysics
• Molecular Biophysics
• Structural Biology
• +۶ مورد دیگر

Prof. Andreas Bausch holds the Heinz Nixdorf Endowed Chair of Cell Biophysics at the Technical University of Munich (TUM) within the TUM School of Natural Sciences . His research focuses on cellular biophysics , particularly the mechanical properties of cytoskeletal networks and self-organization mechanisms in biological systems, with applications in biomimetic materials and organoid modeling. Research Areas : Cytoskeletal mechanics, active matter systems, organoid morphogenesis, integrin signaling, synthetic cell models Techniques : Microrheology, in vitro reconstitution, microfluidics, advanced imaging His work has produced over 100 publications in Nature, Science, PNAS , and Physical Review Letters , with recent emphasis on pancreatic cancer organoids and artificial cell membranes . Key findings include: Discovery of topological excitations governing endothelial cell ordering Elucidation of PIP2/PIP3 regulation in integrin phase separation Development of 3D patterned organoid systems for drug screening Major awards include: ERC Synergy Grant (2018) ERC Advanced Grant (2012) ERC Starting Grant (2011) Berlin-Brandenburg Academy of Sciences Prize (2014) He serves as founding director of the Center for Functional Protein Assemblies (CPA) since 2015 and teaches biomechanics , biophysics , and protein assemblies at TUM. His lab investigates both fundamental biophysical principles and their medical applications in cancer and cardiovascular systems.

• Skeletal Muscle Growth
• Ribosome Biogenesis
• Exercise Physiology
• +۴ مورد دیگر

Gustavo Nader, Ph.D., is a Professor of Kinesiology at The Pennsylvania State University's College of Health and Human Development, where he holds the Dorothy Foehr Huck and J. Loyd Huck Endowed Chair in Molecular, Cellular and Integrative Physiology. His research laboratory at 101 Noll Lab focuses on molecular mechanisms of skeletal muscle adaptation, employing human, animal, and cellular models to investigate ribosome biogenesis, transcriptional regulation, and muscle growth control in contexts ranging from exercise hypertrophy to cancer cachexia. Dr. Nader's research examines fundamental processes including: Ribosome biogenesis and its role in muscle growth regulation Epigenetic control of RNA Polymerase I activity Molecular pathways in mechanical overload-induced hypertrophy Tumor-induced muscle wasting mechanisms Biomimicry approaches inspired by hibernator physiology His work spans exercise physiology, cancer biology, and environmental stress responses. Analysis of his 15 most recent publications (2015-2025) reveals predominant themes in muscle hypertrophy mechanisms, cancer cachexia pathophysiology, ribosomal function analysis, and environmental stress impacts on muscle. His work consistently integrates molecular techniques with physiological models across species. Notable scientific recognitions include: Dorothy Foehr Huck and J. Loyd Huck Chair appointment (2024) Huck Institutes Leadership Fellowship (2025-2026) Dr. Nader leads an active research team investigating muscle plasticity, with current projects funded through the Huck Institutes of the Life Sciences. He collaborates extensively through Penn State's Integrative and Biomedical Physiology graduate program and Center for Cellular Dynamics.